Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential.

about

Breast Cancer Vaccines: New Insights.Study of the tumor microenvironment during breast cancer progression.Immunotherapy for Breast Cancer: Current and Future Strategies.Altered monocyte differentiation and macrophage polarization patterns in patients with breast cancer.

P2860

Q42683276-25A4139B-B6FF-4184-91BA-71D56BEA41DA Q47159979-A6B41571-268A-4FC0-9D33-D98A45622806 Q52587066-3FA2E8FB-2979-46D6-BD5A-279CF1F388EC Q52609522-42EAAA9F-6CBF-4C3A-A593-4D5B0A5175DD

P2860

Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential.

Item

http://www.wikidata.org/entity/Q38948901

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Restoring anti-oncodriver Th1 ...... ancer: progress and potential.

@en

type

Item

label

Restoring anti-oncodriver Th1 ...... ancer: progress and potential.

@en

prefLabel

Restoring anti-oncodriver Th1 ...... ancer: progress and potential.

@en

P1476

Restoring anti-oncodriver Th1 ...... ancer: progress and potential.

@en

P2093

Brian J Czerniecki

http://www.w3.org/2001/XMLSchema#string

Lucy M De La Cruz

http://www.w3.org/2001/XMLSchema#string

Nadia F Nocera

http://www.w3.org/2001/XMLSchema#string

P2860

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab

Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy.

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

The blockade of immune checkpoints in cancer immunotherapy

PD-1 and its ligands in tolerance and immunity

P304

1219-1232

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/IMT-2016-0052

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27605070

http://www.w3.org/2001/XMLSchema#string

P932

5967360

http://www.w3.org/2001/XMLSchema#string

Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential.

about

P2860

P2860

Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932